Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT
- PMID: 32606043
- DOI: 10.1136/annrheumdis-2020-217359
Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT
Abstract
Objective: To prospectively investigate whether differences in pulmonary vasculature exist in systemic sclerosis (SSc) and how they are distributed in patients with different pulmonary function.
Methods: Seventy-four patients with SSc undergoing chest CT scan for interstitial lung disease (ILD) screening or follow-up were prospectively enrolled. A thorough clinical, laboratory and functional evaluation was performed the same day. Chest CT was spirometry gated at total lung capacity and images were analysed by two automated software programs to quantify emphysema, ILD patterns (ground-glass, reticular, honeycombing), and pulmonary vascular volume (PVV). Patients were divided in restricted (FVC% <80, DLco%<80), isolated DLco% reduction (iDLco- FVC%≥80, DLco%<80) and normals (FVC%≥80, DLco%≥80). Spearman ρ, Mann-Whitney tests and logistic regressions were used to assess for correlations, differences among groups and relationships between continuous variables.
Results: Absolute and lung volume normalised PVV (PVV/LV) correlated inversely with functional parameters and positively with all ILD patterns (ρ=0.75 with ground glass, ρ=0.68 with reticular). PVV/LV was the only predictor of DLco at multivariate analysis (p=0.007). Meanwhile, the reticular pattern prevailed in peripheral regions and lower lung thirds, PVV/LV prevailed in central regions and middle lung thirds. iDLco group had a significantly higher PVV/LV (2.2%) than normal (1.6%), but lower than restricted ones (3.8%).
Conclusions: Chest CT in SSc detects a progressive increase in PVV/LV as DLco decreases. Redistribution of perfusion to less affected lung regions rather than angiogenesis nearby fibrotic lung may explain the results. Further studies to ascertain whether the increase in PVV/LV reflects a real increase in blood volume are needed.
Keywords: arterial hypertension; cardiovascular disease; disease activity; pulmonary fibrosis; systemic sclerosis.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MO reports grants from Gruppo Italiano Lotta Sclerodermia (GILS), grants from Fondazione Italiana Ricerca Artrite (FIRA), during the conduct of the study; grants from Menarini Foundation, personal fees from Novartis, outside the submitted work. CB and DG report personal fees from Actelion, outside the submitted work. MM-C reports grants from FIRA, grants from GILS, during the conduct of the study; grants and personal fees from Actelion, personal fees from Biogen, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Eli-Lilly, outside the submitted work. ST reports grants and personal fees from Roche, personal fees from Boehringer-Ingelheim, outside the submitted work. GCa, GCi, GCu, AF, SC, SB-R, AB, MB and FL have no COI disclosures.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical